Grand Pharmaceutical Group Ltd banner
G

Grand Pharmaceutical Group Ltd
HKEX:512

Watchlist Manager
Grand Pharmaceutical Group Ltd
HKEX:512
Watchlist
Price: 6.22 HKD -2.96% Market Closed
Market Cap: HK$22.1B

P/FCFE

21
Current
80%
More Expensive
vs 3-y average of 11.7

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
21
=
Market Cap
HK$23.7B
/
Free Cash Flow to Equity
HK$996.4m

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
21
=
Market Cap
HK$23.7B
/
Free Cash Flow to Equity
HK$996.4m

Valuation Scenarios

Grand Pharmaceutical Group Ltd is trading above its 3-year average

If P/FCFE returns to its 3-Year Average (11.7), the stock would be worth HK$3.46 (44% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-44%
Maximum Upside
No Upside Scenarios
Average Downside
38%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 21 HK$6.22
0%
3-Year Average 11.7 HK$3.46
-44%
5-Year Average 12.6 HK$3.74
-40%
Industry Average 13.9 HK$4.1
-34%
Country Average 13.9 HK$4.1
-34%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
HK
Grand Pharmaceutical Group Ltd
HKEX:512
21.8B HKD 21 16.9
US
Eli Lilly and Co
NYSE:LLY
883B USD 67.5 44.2
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 21.1 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 27.5 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 36.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 9.4 20.7
US
Merck & Co Inc
NYSE:MRK
270.2B USD 12.3 15.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD -766.6 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 24.3 12.1
US
Pfizer Inc
NYSE:PFE
151.8B USD 24.4 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 19.4 16.7
P/E Multiple
Earnings Growth PEG
HK
G
Grand Pharmaceutical Group Ltd
HKEX:512
Average P/E: 21.9
16.9
18%
0.9
US
Eli Lilly and Co
NYSE:LLY
44.2
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
26.1
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.3
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.7
16%
1

Market Distribution

In line with most companies in Hong Kong
Percentile
67th
Based on 1 043 companies
67th percentile
21
Low
0.3 — 7.1
Typical Range
7.1 — 22.8
High
22.8 —
Distribution Statistics
Hong Kong
Min 0.3
30th Percentile 7.1
Median 13.9
70th Percentile 22.8
Max 11 983

Grand Pharmaceutical Group Ltd
Glance View

Market Cap
22.1B HKD
Industry
Pharmaceuticals

Grand Pharmaceutical Group Ltd. stands as a significant player in the pharmaceutical industry, strategically positioned in the bustling hub of the Asia-Pacific region. Founded with a vision to harness scientific innovation for healing, the company has diligently expanded its reach and capabilities over the years. Grand Pharma is meticulously structured around three core segments: Medicine and Healthcare, Biopharmaceutical Manufacturing, and Medical Devices. In the Medicine and Healthcare segment, it advances an extensive portfolio of both proprietary and generic drugs. This segment alone accounts for a substantial portion of its revenue, capitalizing on its adeptness in research and development to maintain a robust pipeline of products. By continuously innovating and seeking to meet unmet medical needs, Grand Pharma sustains its competitive edge in the market. Their Biopharmaceutical Manufacturing segment shines brightly as a beacon of future growth, showcasing their commitment to biotechnology. Here, Grand Pharmaceutical leverages cutting-edge biotechnologies to develop therapies targeting a range of complex diseases. This segment is noted for its high-margin potential, driven by the increasing global demand for biologics. Furthermore, their Medical Devices segment complements the pharmaceutical operations by delivering state-of-the-art products in areas such as cardiovascular health and surgical equipment. By maintaining a balanced and diversified portfolio across these business areas, Grand Pharmaceutical effectively mitigates risks and capitalizes on emerging trends in global healthcare markets. Through astute strategic planning and an unwavering commitment to quality and innovation, the company fortifies its position as a leader in the field, continually reinvesting its profits to further enhance its offerings and broaden its impact.

Intrinsic Value
5.88 HKD
Overvaluation 6%
Intrinsic Value
Price HK$6.22
G
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett